Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 23, 2023 - Issue 3
Submit an article Journal homepage
1,970
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Rationale for combining tyrosine kinase inhibitors and T cell redirecting antibodies to mitigate cytokine release syndrome (CRS)

Gabrielle Leclercq-cohenRoche Innovation Center Zurich, Roche Pharma Research and Early Development, pRED, Schlieren, SwitzerlandCorrespondence[email protected]
View further author information
,
Marina BacacRoche Innovation Center Zurich, Roche Pharma Research and Early Development, pRED, Schlieren, SwitzerlandView further author information
&
Christian KleinRoche Innovation Center Zurich, Roche Pharma Research and Early Development, pRED, Schlieren, SwitzerlandView further author information
Pages 223-225 | Received 18 Oct 2022, Accepted 06 Jan 2023, Published online: 29 Jan 2023

References

  • Bacac M, Colombetti S, Herter S, et al. CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies. Clin Cancer Res. 2018Oct1;24(19):4785–4797. PubMed PMID: WOS:000446207700018; English.
  • Bacac M, Klein C, Cea Tcb: UP. A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016Aug;5(8):e1203498. PubMed PMID: 27622073; PubMed Central PMCID: PMCPMC5007959.
  • Augsberger C, Hänel G, Xu W, et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. 2021 dec 23;138(25):2655–2669.
  • Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018Jun15;6(1):56. PubMed PMID: 29907163; PubMed Central PMCID: PMCPMC6003181. eng.
  • Leclercq G, Servera LA, Danilin S, et al. Dissecting the mechanism of cytokine release induced by T-cell engagers highlights the contribution of neutrophils. OncoImmunology. 2022 Dec 31;11(1):2039432.
  • Leclercq G, Haegel H, Toso A, et al. JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy. J Immunother Cancer. 2022;10(1):e003766.
  • Leclercq G, Haegel H, Schneider A, et al. Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies. J Immunother Cancer. 2021;9(7):e002582.
  • Leonard JT, Kosaka Y, Malla P, et al. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL. Blood. 2021Feb18;137(7):939–944. PubMed PMID: 32898857; eng.
  • Uy GL, Rettig MP, Christ S, et al. Prophylactic ruxolitinib for cytokine release syndrome (CRS) in relapse/refractory (R/R) AML patients treated with flotetuzumab. Blood. 2020;136(Supplement 1):19–21.
  • Leclercq G, Steinhoff N, Haegel H, et al. Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors. OncoImmunology. 2022 Dec 31;11(1):2083479.
  • Hua H, Kong Q, Zhang H, et al. Targeting mTOR for cancer therapy. J Hematol Oncol. 2019 june 05;12(1):71.
  • Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000Res. 2016; 5. PubMed PMID: 27635236; PubMed Central PMCID: PMCPMC5007757. eng. Doi:10.12688/f1000research.9207.1.
  • Petrazzuolo A, Maiuri MC, Zitvogel L, et al. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy. OncoImmunology. 2022 dec 31;11(1):2077898.
  • Foà R, Bassan R, Vitale A, et al. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in Adults. N Engl J Med. 2020Oct22;383(17):1613–1623. PubMed PMID: 33085860; eng.
  • Zieger N, Kazerani M, Nicholls A, et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood. 2022Jul25. Doi:10.1182/blood.2022015956. PubMed PMID: 35878001; eng.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.